CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis
NASDAQ:CSBR - Nasdaq - US15870P3073 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to CSBR. CSBR was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of CSBR have multiple concerns. CSBR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CSBR was profitable.
CSBR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CSBR reported negative net income in multiple years.
In multiple years CSBR reported negative operating cash flow during the last 5 years.
1.2 Ratios
CSBR's Return On Assets of -2.37% is fine compared to the rest of the industry. CSBR outperforms 66.67% of its industry peers.
The Return On Equity of CSBR (-87.81%) is worse than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.37% | ||
| ROE | -87.81% | ||
| ROIC | N/A |
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 44.75%, CSBR is in line with its industry, outperforming 47.37% of the companies in the same industry.
CSBR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CSBR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
CSBR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CSBR has more shares outstanding
Compared to 5 years ago, CSBR has more shares outstanding
There is no outstanding debt for CSBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CSBR has an Altman-Z score of 0.70. This is a bad value and indicates that CSBR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CSBR (0.70) is worse than 61.40% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that CSBR is not too dependend on debt financing.
CSBR has a Debt to Equity ratio of 0.21. This is comparable to the rest of the industry: CSBR outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.7 |
ROIC/WACCN/A
WACC11.32%
2.3 Liquidity
CSBR has a Current Ratio of 0.75. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CSBR (0.75) is worse than 92.98% of its industry peers.
A Quick Ratio of 0.75 indicates that CSBR may have some problems paying its short term obligations.
CSBR's Quick ratio of 0.75 is on the low side compared to the rest of the industry. CSBR is outperformed by 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 101.41%, which is quite impressive.
Looking at the last year, CSBR shows a small growth in Revenue. The Revenue has grown by 7.20% in the last year.
Measured over the past years, CSBR shows a quite strong growth in Revenue. The Revenue has been growing by 13.13% on average per year.
EPS 1Y (TTM)101.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
Revenue 1Y (TTM)7.2%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%16.56%
3.2 Future
CSBR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.10% yearly.
CSBR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.84% yearly.
EPS Next Y143.71%
EPS Next 2Y58.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.96%
Revenue Next 2Y12.51%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 1017.00, which means the current valuation is very expensive for CSBR.
The rest of the industry has a similar Price/Earnings ratio as CSBR.
CSBR's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.63.
Based on the Price/Forward Earnings ratio of 41.54, the valuation of CSBR can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CSBR is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, CSBR is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1017 | ||
| Fwd PE | 41.54 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSBR is valued a bit cheaper than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 96.3 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CSBR does not grow enough to justify the current Price/Earnings ratio.
CSBR's earnings are expected to grow with 58.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)7.08
PEG (5Y)N/A
EPS Next 2Y58.1%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CSBR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.17
-0.32 (-3.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners47.82%
Inst Owner Change-89.47%
Ins Owners25.86%
Ins Owner Change2.27%
Market Cap140.55M
Analysts82.86
Price Target8.16 (-19.76%)
Short Float %1.02%
Short Ratio1.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)424.84%
Min EPS beat(2)390.2%
Max EPS beat(2)459.48%
EPS beat(4)3
Avg EPS beat(4)198.59%
Min EPS beat(4)-161.44%
Max EPS beat(4)459.48%
EPS beat(8)4
Avg EPS beat(8)36.58%
EPS beat(12)6
Avg EPS beat(12)-2.08%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.76%
Min Revenue beat(2)1.31%
Max Revenue beat(2)4.22%
Revenue beat(4)3
Avg Revenue beat(4)0.28%
Min Revenue beat(4)-12.56%
Max Revenue beat(4)8.16%
Revenue beat(8)3
Avg Revenue beat(8)-2.66%
Revenue beat(12)6
Avg Revenue beat(12)-1.22%
Revenue beat(16)10
Avg Revenue beat(16)-0.4%
PT rev (1m)0%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)85.71%
EPS NY rev (1m)0%
EPS NY rev (3m)61.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1017 | ||
| Fwd PE | 41.54 | ||
| P/S | 2.62 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 206.39 | ||
| P/tB | 406.21 | ||
| EV/EBITDA | 96.3 |
EPS(TTM)0.01
EY0.1%
EPS(NY)0.24
Fwd EY2.41%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS3.88
BVpS0.05
TBVpS0.03
PEG (NY)7.08
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.37% | ||
| ROE | -87.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.75% | ||
| FCFM | N/A |
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
F-Score4
Asset Turnover2.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.1 | ||
| Cap/Depr | 6.1% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 0.7 |
F-Score4
WACC11.32%
ROIC/WACCN/A
Cap/Depr(3y)106.12%
Cap/Depr(5y)172.76%
Cap/Sales(3y)3.95%
Cap/Sales(5y)5.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
EPS Next Y143.71%
EPS Next 2Y58.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.2%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%16.56%
Revenue Next Year14.96%
Revenue Next 2Y12.51%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
EBIT growth 1Y95.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-147.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.21%
OCF growth 3YN/A
OCF growth 5YN/A